TY - JOUR AU - Rayman, G. AU - Lumb, A. AU - Kennon, Brian AU - Cottrell, C. AU - Nagi, Dinesh AU - Page, E. AU - Voigt, D. AU - Courtney, H.C. AU - Atkins, H. AU - Platts, J. AU - Higgins, Katie AU - Dhatariya, K. AU - Patel, Mayank AU - Narendran, Parth AU - Kar, Partha AU - Newland-Jones, P. AU - Stewart, R. AU - Burr, O. AU - Thomas, S. PY - 2020 DA - June TI - Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic JO - Diabetic Medicine EP - 1216 VL - 37 IS - 7 DO - https://doi.org/10.1111/dme.14328 AB - During the early stages of the COVID‐19 pandemic, hospitals in London, the UK epicentre, reported an unusually high number of people presenting with COVID‐19 disease developing diabetic ketoacidosis, hyperosmolar hyperglycaemic state, or a combination of both. Very high doses of insulin were often needed to manage the hyperglycaemia. It has been proposed that these metabolic disturbances may result from severe insulin resistance combined with decreased insulin secretion due to beta cell dysfunction. PB - Wiley UR - https://discovery.dundee.ac.uk/en/publications/b3729420-7429-44ce-8211-977244a5e9e4 KW - Coronavirus (COVID-19) ER